Replies to post #114116 on Savvy Trades and Investments

[wadegarret]

bbotcs- GERN

I owned a company back in 2015 named Relypsa(RLYP). They had only one competitor for treating high potassium levels. They got FDA approval in Oct, and got bought out 6 months later in April 2016. GERN's drug is blockbuster IMO, and has only one competitor Brystol Myers Sqiubb. Brystol Myers just did $364M for their drug Reblozyl, which treats MDS. Except GERNs drug Rytelo treats 4 times as many low risk MDS patients, as it treats all cell types vs Reblzyl only effectively treats 25% of them. Point being, if Brysrol Myers is already(Reblozyl is pretty new) going at the pace of $1.2B year treating low risk MDS, just imagine the potential for GERNs drug !